Impaired neuronal sodium channels cause intranodal conduction failure and reentrant arrhythmias in human sinoatrial node by Li, Ning et al.
ARTICLE
OPEN
Impaired neuronal sodium channels cause 
intranodal conduction failure and reentrant 
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M echanism s for human sinoatrial node (S A N ) dysfunction are poorly understood and 
whether human SAN excitability requires voltage-gated sodium channels (N a v ) rem ains 
controversia l. H ere , we report that neuronal (n )N av  blockade and selective nNav1.6 blockade 
during high-resolution optical mapping in explanted human hearts depress intranodal SAN 
conduction, which worsens during autonom ic stimulation and overdrive suppression to 
conduction failure. Partial cardiac (c )N av  blockade further im pairs autom aticity and intra­
nodal conduction, leading to beat-to-beat variab ility and reentry. M ultiple nNav transcripts 
are higher in SAN vs atria; heterogeneous alterations of several isoform s, specifica lly nNav1.6, 
are associated with heart failure and chronic alcohol consumption. In silico sim ulations of Nav 
distributions suggest that ZNa is essential for SAN conduction, especially in fibrotic failing 
hearts. Our results reveal that not only cNav but nNav are also integral for preventing 
disease-induced failure in human SAN intranodal conduction. D isease-im paired nNav may 
underlie patient-specific SAN dysfunctions and should be considered to treat arrhythm ias.
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COMMUNICATIONS
Normal cardiac rhythm is maintained by the human sinoatrial node (SAN) complex, which is compartmen­talized into multiple intranodal pacemakers and con­
duction pathways (sinoatrial conduction pathways, SACPs) 
within an intramural three-dimensional (3D) structure1-3. Robust 
SAN pacemaking and conduction is maintained amidst a plethora 
of internal and external perturbations by several ion channels, 
which are heterogeneously expressed within the SAN compart- 
ments3-5. Impairment of pacemaking or conduction between 
SAN compartments can result from a variety of cardiac pathol­
ogies or extrinsic factors (e.g., antiarrhythmic drugs) and may 
lead to SAN dysfunction (SND), a disease that can significantly 
impact quality of life6. In addition to rhythm abnormalities, SND 
can often facilitate deterioration to atrial fibrillation (AF)7 and 
heart failure (HF)8.
Currently, patients with symptomatic SND rely on a single 
treatment option of electrical pacemaker implantation9, which 
acts as a crutch to support but not heal the heart. The develop­
ment of optimal alternative treatments for SND will require in­
depth knowledge of the mechanisms involved in robust human 
SAN rhythm regulation. However, there is a paucity of studies 
addressing mechanisms that contribute to automaticity and 
intranodal conduction directly in the human SAN complex at the 
molecular, cellular, and tissue levels. Disease-induced remodeling 
of many of the molecular components critical to SAN function 
including hyperpolarization-activated cyclic nucleotide-gated 
(HCN) channels and G-protein-coupled inwardly rectifying 
potassium channels, adenosine receptors (A1R), and L-type cal­
cium channels, as well as structural fibrotic remodeling can lead 
to SND3’10- 13. However, majority of these molecular components 
critical to SAN function have been studied only in animal mod- 
els5, which have significantly different functional and anatomical 
features compared with the human SAN, especially when 
studying aged/diseased human SAN with SND. In particular, the 
roles of voltage-gated sodium channels (Nav), which are major 
contributors to cardiac and neuronal excitability, remain con­
troversial in human SAN pacemaking and conduction. Although 
the presence of Nav has been reported in the SAN from multiple 
species14- 16, direct evidence confirming the expression and 
functional role of cardiac (cNav) and/or neuronal (nNav) iso­
forms in the hum an SAN is lacking17. Some patients with 
symptomatic SND are found to harbor loss-of-function m uta­
tions in the SCN5A gene, which encodes the a-subunit o f the 
cardiac isoform Nav1.5 (ref.18), suggesting that functional 
voltage-gated Na+ current (1Na) may be necessary for m ain­
taining hum an SAN pacemaking and conduction. Furthermore, 
although antiarrhythmic drugs that block Nav have been shown 
to inadvertently unmask SND in patients predisposed to the 
arrhythm ia19-21, no study has determined the specific Nav 
isoform(s) mediating this detrimental effect on the hum an SAN. 
Hence, there is a critical need to determine the functional 
contributions of Nav channels in maintaining SAN robustness, 
by studying their role directly in the unique 3D hum an SAN
complex2-4.
Therefore, the primary goal of the current study is to determine 
the existence and specific role of nNav and cNav isoforms in 
human SAN pacemaking and intranodal conduction, and to 
reveal their disease-induced alterations in explanted human 
hearts. Some of the comorbidities associated with the explanted 
human hearts used in this study include, but are not limited to, 
HF, AF, hypertension (HTN), and modifying risk factors such as 
smoking, chronic alcohol consumption, and drug abuse (Sup­
plementary Tables 1 and 2). We employed high-resolution near- 
infrared sub-surface optical mapping, the only approach currently 
able to reveal intramural human SAN pacemaking and conduc­
tion. Furthermore, our functional studies are complemented by
human SAN computational simulations and molecular mapping 
of multiple nNav and cNav transcripts and protein expression.
Here, we report that in the human SAN, nNav mainly con­
tribute to intranodal conduction, whereas cNav play dual roles in 
both pacemaking and conduction. Impairment of Nav can lead 
not only to depression of SAN pacemaker and conduction but 
also to a perfect storm of SAN exit block, disorganized intranodal 
pacemakers, and SAN micro- and macro-reentry. Our data also 
suggest that by altering nNav in the SAN and/or atria, HF and 
chronic alcohol consumption could promote a patient-specific, 
mechanistic substrate for tachy-brady arrhythmias and SAN 
conduction blocks.
Results
Essential roles of Navs under physiological conditions. Under 
control conditions, all optically mapped human hearts (non­
failing n =  12 and HF n =  2) exhibited stable intrinsic sinus 
rhythm of 56 to 116 beats per minute, with a sinus cycle length 
(SCL) of 729 ± 200 ms (Supplementary Table 1 and Supplemen­
tary Fig. 1). These values are comparable with “intrinsic” rates 
reported in vivo during autonomic blockade in adult human 
subjects with/without cardiac comorbidities22-24. For more 
details on the stability and experimental protocols, please see the 
Methods section. All functional data presented below are averages 
of all human SAN preparations (HF and non-failing) studied for 
each specific drug protocol. As the small sample size precludes 
subset analysis, heart-specific data are presented in Supplemen­
tary Fig. 1.
Tetrodotoxin (TTX) dose-dependently prolonged SCL by 6 ± 
5% (mean ± SD, n =  8, P < 0.05, Wilcoxon’s test) at 100 nM and 
43 ± 41% (n =  7, P < 0.05, Wilcoxon’s test) at 1-3 pM, and caused 
shifts of the intranodal leading pacemaker and preferential SACP 
(Fig.1; Table 1). Sinoatrial conduction time at sinus rhythm 
(SACTsr) was increased to ~250% (n =  6, P <0.05, Wilcoxon’s 
test) by TTX 100 nM and to ~610% (n =  6, P <0.05, t-test) by 
TTX 1-3 pM. Figure 2a, b shows the effects of TTX 1 pM on SCL 
and SACTsr. Furthermore, TTX 1-3 pM significantly increased 
SACTsr/SCL ratio from 8% to 23% (P < 0.01), suggesting that 
prolongation of atrial CL by cNav blockade was primarily due to 
depression of SAN conduction rather than automaticity.
Nav blockade also prolonged intranodal conduction (measured 
from the SAN leading pacemaker to the SAN border) by 31% and 
47% (P <0.05, t-test) at TTX 100 nM and 1-3 pM, respectively 
(Fig. 2c, d). Decremental SAN conduction (Fig. 2c) gradually 
increased SACTsr and eventually caused exit block (5/7 hearts) 
and complete atrial arrest (3/7 hearts) at TTX 1-3 pM. We also 
observed significantly higher beat-to-beat variations of SCL and 
SACT during TTX 1-3 pM than at control conditions or TTX 
100 nM (Fig. 2e and Supplementary Fig. 2).
To eliminate the possibility of natural drift of tissue 
properties affecting our results during the experimental 
mapping period of 2 h, we verified in all studied hum an SAN 
experiments as well as in previous experiments3 that the drift at 
baseline conditions in SCL was ~5% per hour, whereas drift was 
not observed in atrial conduction velocity (CV), which suggests 
that changes in automaticity and conduction seen with low- and 
high-dose TTX, respectively, were significant and not due to 
tim e-dependent changes in tissue properties (Supplementary 
Fig. 3).
Protective roles of Navs during stress in the human SAN. We
next investigated the contribution of Nav in protecting SAN 
conduction during metabolic challenge with adenosine bolus or 
overdrive suppression by fast atrial pacing, which are clinically 
employed tests to unmask SND25,26. Adenosine bolus was
Fig. 1 High-resolution near-infrared optical mapping (NIOM) reveals effect of nNav and cNav blockade on human SAN intramural activation. a Left: 
human SAN preparation and optical mapping field of view (O FV). Activation maps of Heart 228749 at control (middle) and during 100 nM TTX  perfusion 
(right). Dot indicates the leading pacemaker inside the sinoatrial node (SAN); asterisk indicates the earliest atrial activation site (EAS); arrow indicates the 
sinoatrial conduction pathway (SACP). b TTX  effects on sinus cycle length (SCL) and sinoatrial conduction time at sinus rhythm (SACTsr). c Locations of 
SAN leading pacemaker (dots), earliest atrial activation site, and sinoatrial conduction pathways at control (left, n =  10), during perfusion of 100 nM 
(middle, n = 8), and 1-3 pM TTX  (right, n = 7). Data presented as mean ± SD. CT crista terminalis, n/cNav neuronal/cardiac sodium channels, OAP optical 
action potential, RA (A ) right atrial (appendage), S/IVC superior/inferior vena cava, TTX  tetrodotoxin. Source data are provided as a Source Data file.
Table 1 Effects of Nav blockade on human SAN and atrial conduction
100 nM TTX % Control 
±SD
n P-value 1-3 pM TTX % Control 
±SD
n P-value Nav1.6 blocker % 
Control ± SD
n P-value
SCL 106 ±5% 8 0.0141 143 ±41% 7 0.0156 106 ± 6% 5 0.1000
SACTsr 250 ±201% 6 0.0313 610 ± 355% 6 0.017 120% 1
2 Hz SACTppb 319 ±148% 6 0.0152 407 ± 272% 5 0.0651 1277% 1
2 Hz cSNRTi 236 ± 234% 7 0.1763 139 ± 118% 3 0.6224 226 ± 259% 5 0.3125
2 Hz cSNRTd 137 ± 185% 6 0.8438 4 ±141% 4 0.2651 17% 1
RA CV longitudinal 94 ± 4% 5 0.0327 70 ± 14% 6 0.0036 94 ±10% 5 0.2684
RA CV transverse 88 ± 19% 5 0.0074 68 ± 23% 6 0.0212 100 ± 10% 5 0.9590
cSNRTd/i corrected direct/indirect sinus node recovery time, RA right atrial, SACTsr/ppb sinoatrial conduction time at sinus rhythm/post-pacing beat, SAN  sinoatrial node, SCL sinus cycle length. Percent 
data are reported as mean±SD. Normality assumption was verified using Shapiro-Wilk test. Parametric data were analyzed with two-sided t-test. Non-parametric data were analyzed with two-sided 
Wilcoxon's test. Source data are provided as a Source Data file
injected via the coronary artery in eight SAN preparations, which 
caused temporary hyperpolarization of the cardiomyocytes. At 
control conditions, adenosine bolus increased the maximum SCL 
by 30% ± 20%, whereas after 100 nM TTX, the same dose of 
adenosine prolonged SCL by 72 ± 54% (n =  8, P < 0.05, t-test) 
(Fig. 3). Moreover, SAN exit block was observed in five of eight 
hearts during adenosine bolus at 100 nM TTX, which did not 
occur at control conditions (Fig. 3).
Based on our molecular data that showed transcripts of 
nNav1.6 isoform to be higher in the SAN compared with other 
nNav isoforms (see below), we studied its unique role in SAN 
pacemaking and conduction using a specific nNav1.6 blocker 30 
nM 4,9-Anhydrotetrodotoxin27 in five human SAN experiments 
(Fig. 3c and Supplementary Fig. 4). These experiments revealed 
that selective blockade of nNav1.6 channels did not affect SCL but 
could depress SAN conduction and induced SAN exit block in
Fig. 2 SAN intranodal conduction impaired by nNav and cNav blockade. Activation map (left) and OAP recordings (right) show sinoatrial node (SAN) 
activation and conduction at control (a), and after blocking cardiac Nav with 1 pM TTX  ( b). Dot indicates the leading pacemaker inside the SAN; asterisk 
indicates the earliest atrial activation site; arrow indicates the SAN conduction pathway. c Left: SAN activation map showing intranodal conduction at 
control condition. Middle to right: SAN activation maps of four sequential beats showing the gradual decrease of intranodal conduction and SAN macro­
reentry after cardiac Nav blockade with 1 pM TTX. White arrows indicate the direction of intranodal conduction; numbers beside arrows denote SAN 
conduction velocity (cm /s). d Summary of SAN conduction velocity (C V ) changes at 100 nM and 1-3 pM TTX  (n = 5) compared with control (n = 6). 
e TTX  increased the beat-to-beat variation shown as SD (STDEV) of SAN (control: n = 10; TTX  100 nM and 1-3 pM: n = 7) and atrial (control: n = 10; TTX 
100 nM: n = 7; 1-3 pM: n = 5) cycle length (CL), and sinoatrial conduction time (SACT) during control (n = 6), TTX  100 nM (n = 5), and TTX  1-3 pM (n = 
4). Data presented as mean ± SD. IVC inferior vena cava, OAP optical action potential, RA (A ) right atrial (appendage), TTX  tetrodotoxin. Data in d and e 
were represented in mean±SD. Asterisks in d and e indicate P < 0.05 vs. control by two-tailed t-test. Source data are provided as a Source Data file.
three out of five experiments, during adenosine bolus and 
overdrive suppression; these results were comparable to the 
effects of 100 nM TTX (Fig. 3c). Our findings suggest that 
nNav1.6 blockade could be one of the contributors of the 100 nM 
TTX inhibitory effect on SAN conduction, thereby emphasizing 
its role as an important functional nNav isoform for human SAN 
conduction. We also evaluated the effect of TTX and nNav1.6 
blocker on atrial conduction during pacing at 500 ms; nNav1.6 
did not have a significant effect on both longitudinal and
transversal CV but TTX depressed longitudinal atrial CV by 6% 
and 30% (P < 0.01, t-test) at 100 nM and 1-3 pM concentrations, 
respectively (Table 1 and Supplementary Fig. 5).
At control conditions, atrial pacing at 500 ms did not unmask 
SND (cSNRTi > 525 ms) in any of the hearts tested (n =  14). 
After selectively blocking nNav with TTX 100 nM, the same rate 
of atrial pacing increased cSNRTi by 236 ± 234% (n =  7, P =  
0.176, Wilcoxon’s test) and unmasked SND in two hearts (HF 
421856 and non-failing 642519; Supplementary Table 1) with
Fig. 3 Protective role of nNav in human SAN conduction during hyperpolarization and overdrive pacing. a Top: optical action potentials (OAPs) show a 
slight increase of sinus cycle length (SCL) during SAN hyperpolarization with 30 pM adenosine bolus at control conditions. Bottom: OAPs show exit block 
from the SAN to the RA after neuronal Nav blockade with 100 nM TTX  during adenosine bolus. b Top: OAPs show normal SNRT and 1:1 conduction from 
the SAN to the RA after 500 ms atrial pacing at control conditions; bottom: OAPs show prolonged SNRT and 2:1 exit block from the SAN to the RA after 
500 ms atrial pacing during 100 nM TTX  pefusion. c Left: comparison of SCL prolongation caused by adenosine bolus at control conditions (n = 8), 30 nM 
nNav1.6 blocker (n = 5), and during 100 nM TTX  perfusion (n = 8); right: exit block events observed at control conditions, 30 nM nNav1.6 blocker and 
during 100 nM TTX  perfusion after adenosine bolus. ppb post-pacing beat, RA right atria, SAN sinoatrial node, SNRTi/d indirect/direct sinoatrial recovery 
time, TTX  tetrodotoxin. Data of SCL prolongation in c were represented in mean ± SD, n = 8, *P < 0.05, by t-test. Analysis of exit block events used two­
sided proportion test with Yates continuity correction. Source data are provided as a Source Data file.
cSNRTi > 1400 ms due to exit block (Fig. 3; Table 1). Faster, 300 
ms atrial pacing caused exit block in 3/15 experiments at control 
conditions, in 2/5 experiments with nNav1.6 blocker, in 3/7 
experiments at TTX 100 nM, and in 5/6 hearts at TTX 1-3 pM. 
Figure 4 shows an example of conduction failure/arrhythmias, 
resulting from a perfect storm of stochastic SAN exit block, 
competing intranodal pacemakers, SAN micro- and macro­
reentry, seen in two hearts (non-failing 118258 with history of 
chronic HTN/chronic alcohol consumption and HF 930597; 
Supplementary Table 1). In these hearts, preferential slowing of
SAN conduction by Nav blockade, led to intranodal unidirec­
tional blocks and initiated intranodal micro-reentry or macro­
reentry (Supplementary Movies 1 and 2). The micro-reentry pivot 
waves anchored to the longitudinal block region can produce 
both tachycardia and paradoxical bradycardia (due to exit block), 
despite an atrial activation pattern and ECG morphology 
identical to regular sinus rhythm28. Intranodal longitudinal 
conduction blocks usually coincided with interstitial fibrosis 
strands and SAN artery as in the case of heart 118258 as shown 
by histology in Fig. 4c. SAN reentrant arrhythmias were not
Fig. 4  Pacing-induced SAN conduction failure and reentrant arrhythmias during nNav and cNav blockade. a Optical action potentials (OAPs) show 
regular sinus rhythm and sinoatrial conduciton after 3.3 Hz atrial pacing at control. b OAPs show irregular sinus rhythm, atrial pause, and arrhythmia after 
3.3 Hz atrial pacing during 1 pM TTX  perfusion. c SAN activation and conduction pattern revealed by high-resolution optical mapping could explain the 
mechanism underlying the post-pacing reentrant arrhythmia during cardiac Nav blockade by 1 pM TTX. Top, schematic of the SAN pacemaker complex 
representing activation pattern for 9 post-pacing beats. Bottom, SAN activation maps and corresponding histology sections show locations of micro­
reentry and macro-reentrant pathways within the SAN complex stucture. Colored dots indicate positions of sinoatrial (SAN) OAPs presented in b. Orange 
arrows show the conduction direction within the SAN and green arrows indicate conduction outside the SAN; asterisk indicates the earliest atrial activation 
site. IAS interatrial septum, RA(A) right atrial (appendage), S/IVC superior/inferior vena cava, SAN sinoatrial node, TTX  tetrodotoxin.
observed at control conditions or with TTX 100 nM in any hearts, 
except in one (957855) experiment during nNa1.6 blockade.
mRNA and protein profiles of Nav in human SAN and atria.
We next studied the relative mRNA and protein expression levels 
of Nav in human SAN tissues, compared with neighboring atria 
(Supplementary Table 3). The distribution of Nav isoforms, 
including nine a-subunits, and four ß-subunits, were analyzed in
human SAN and surrounding atrial tissues by quantitative PCR 
(qPCR). With the exception of SCN10A (Nav1.8), which was 
detected only at low levels in some of the human RA (see Source 
Data file), all other isoforms were detected in human SAN as well 
as in RA at the mRNA level (Fig. 5). SCN5A (Nav1.5) and SCN1B 
(Navß1) were the most abundantly transcribed Nav channel a- 
and ß-subunits in both human SAN and RA, with higher levels in 
RA than in SAN. In contrast, mRNA transcripts of neuronal 
subunits SCN1A (Nav1.1), SCN2A (Nav1.2), SCN8A (Nav1.6),
Fig. 5 Distribution of cNav and nNav subunit mRNA in the human SAN and RA. Summary data of qPCR analysis of different Nav isoform mRNA levels in 
the human sinoatrial node (SAN) and right atrial (RA ) tissue; colored circles indicate individual data points for each human heart. All mRNA values were 
normalized to the ribosomal 18s gene. Nav voltage-gated sodium channels. Data were represented in mean±SD; n = 20 for each group; normality was 
tested with Shapiro-Wilk test; two-sided t-test was used for parametric data and Wilcoxon's test was used for non-parametric data. Source data are 
provided as a Source Data file.
and SCN9A (Nav1.7) were higher in the human SAN than RA. In 
addition, we also quantified the transcript levels of other major 
proteins involved in human SAN pacemaking and conduction 
including HCN1, HCN4, GJA1 (Cx43), GJA5 (Cx40), and calcium 
channels CACNA1C (Cav1.2), CACNA1D (Cav1.3), and CAC- 
NA1G  (Cav3.1). CACNA1D transcripts were significantly higher 
in the SAN vs. RA; as expected, we found higher levels of both 
HCN1 and HCN4, and lower levels of GJA1 transcripts in SAN vs. 
atria, which validated the purity of SAN tissue used for these 
studies (Supplementary Table 3).
Protein distribution patterns of cNav1.5 and nNav1.6 in 
human SAN and RA were also detected by immunostaining 
(Fig. 6a, b). Fluorescence density analysis confirmed that protein 
levels of cNav1.5 channels are higher in RA than in SAN 
cardiomyocytes (P <0.01, pairwise test), whereas the nNav1.6 
protein expression is higher in the SAN than RA (P <0.01,
pairwise test). Localization of cNav1.5 and nNav1.6 is shown to 
be cardiomyocyte specific (Fig. 6c, d and Supplementary Fig. 6). 
Figure 6e shows that the cNav1.5 protein expression pattern 
detected by western blotting is consistent with both mRNA 
expression and immunostaining results. These results collectively 
confirm the presence of both nNav and cNav isoforms in the 
human SAN at the molecular level.
In addition, to correlate functional results with biochemical 
findings the expression levels of cNav1.5 and nNav1.6 were 
quantified in immunostained cryo-frozen tissue sections from 
three hearts functionally mapped with the nNav1.6 blocker 
(957855, 283273, and 670263) (Supplementary Fig. 7). Our results 
show that in heart 957855, which developed exit blocks with 
nNav1.6 blocker (Supplementary Fig. 6), the ratio of nNav1.6 
between SAN and RA was the highest compared with two other 
hearts, which exhibited less sensitivity to nNav1.6 blocker. These
Fig. 6 Protein distribution of cNav1.5 and nNav1.6 in the human SAN and RA. a Left to right: immunofluorescence image showing double staining of 
cNav1.5 (red) and Cx43 (green) in human heart 294050 cryosection with sinoatrial node (SAN) and right atrial (RA) regions (n = 8) separated by white 
dotted line; magnification of image to show the distribution of cNav1.5 in the RA vs. the SAN; bar graph showing fluorescence signal intensity in the human 
SAN vs. RA. b Left to right: immunofluorescence image showing double staining of nNav1.6 (red) and Cx43 (green) in human heart cryosection with SAN 
and RA regions (n = 7) separated by white dotted line; magnification of image to show the distribution of Nav1.6 in the RA vs. the SAN; bar graph showing 
fluorescence signal intensity in the human SAN vs. RA. c Left to right: cNav1.5 (red) and a-actinin (green; staining cardiomyocytes) dual staining; nNav1.6 
(red) and a-actinin (green) dual staining confirm the cardiomyocyte-specific localization of cNav1.5 and nNav1.6. d Serial sections staining cNav1.5, 
nNav1.6, Cx43, and a nerve bundle labeled by anti-tyrosine hydroxylase (TH: staining sympathetic nerves) show that nNav1.6 and cNav1.5 are 
predominantly found in the myocytes relative to nerve bundles. All presented images a-d were collected from human heart 294050. e Left: representative 
immunoblotting bands for cNav1.5, a-actinin (marker of cardiomyocytes), and Cx43. Right: summary data of immunoblotting results of cNav1.5 protein 
distribution in the human SAN (n = 6) and RA (n = 6), compared with GAPDH (middle) and a-actinin (right), respectively. Cx43 connexin-43, GAPDH 
glyceraldehyde 3-phosphate dehydrogenase. Data were represented in mean±SD. For immunostaining, analysis was done using lme4 and emmeans 
packages in R 3.4.4. Predictors included Heart (treated as random effect) and Condition (fixed effect). Pairwise tests between Condition levels were 
adjusted using Tukey's method. Western blotting data analysis was done using two-sided t-test. Source data and uncropped versions of the western blot 
are provided as a Source Data file.
data may begin to explain the distinct functional contribution of 
nNav1.6 channels and correlate these findings with protein 
expression levels.
nNav mRNA altered by HF and chronic alcohol consumption .
As every human heart studied is characterized by cardiac disease, 
aging, and/or comorbidities, we investigated whether mRNA 
profiles of any cNav and nNav are associated with specific disease 
and/or accompanying comorbidities and risk factors. To deter­
mine the contribution of these multiple factors, we screened the 
donor (non-failing) and HF hearts to identify those conditions 
(Supplementary Table 3). There were no significant differences in 
Nav mRNA levels associated with HTN, AF, coronary artery 
disease, gender, age, or illicit drug abuse in the hearts studied 
(Supplementary Tables 4 and 5). However, interestingly, history 
of chronic alcohol consumption was strongly associated with 
downregulation of multiple mRNA transcripts, both in the RA 
and SAN. SCN2A, SCN8A, and SCN3B transcripts were sig­
nificantly downregulated in the RA and SAN of donor non-failing 
hearts with a history of chronic alcohol consumption (5/10 
hearts) (Fig. 7a). Smoking history (5/10 hearts) did not show as 
strong effects as chronic alcohol consumption, with significant 
changes only in SCN4B in RA and SAN (Supplementary Fig. 8a). 
Besides chronic alcohol consumption, HF was also associated 
with significant downregulation of SCN2A, SCN3A, SCN4A, 
SCN9A, SCN2B, and SCN4B in RA but not in the SAN (Sup­
plementary Table 3). Based on our finding that history of chronic 
alcohol consumption can independently modify several nNav 
transcripts, data were further analyzed excluding hearts with 
history of chronic alcohol consumption, to determine the specific 
effect of HF on Nav. Interestingly, four a-subunits and three ß- 
subunits were significantly downregulated in the HF RA, 
including SCN8A encoding the nNav1.6 isoform, which was also 
significantly altered in the HF SAN (Fig. 7b). A positive corre­
lation was also found between heart weight and SCN11A and 
SCN1A in RA and SCN11A and SCN3B in the SAN (Supple­
mentary Fig. 8b). In addition, we also tested whether HF and 
chronic alcohol consumption are associated with differences in 
other major pacemaker ion channels in SAN but found no sig­
nificant correlations (Supplementary Table 3).
Computational modeling of Nav blockade in SAN-SACP-RA 
models. We further explored the compartment-specific role of 
Nav isoforms using two-dimensional (2D) human SAN-SACP- 
RA computer models with and without HF characteristics 
(Figs. 8a, 9a), which incorporated distinctive structural features of 
human SAN and SACP2,3 (Fig. 1). The 2D human SAN-SACP- 
RA computer models generated realistic characteristics (resting 
potentials, upstrokes, and action potential durations) of action 
potentials in SAN and RA regions, respectively (Fig. 8b). The 
computer model was validated by reproducing similar changes of 
SCL and SACT during 1-100 pM adenosine perfusion recorded 
in our previous optical mapping experiments3. Furthermore, the 
computer simulation revealed that impairments in SAN con­
duction during adenosine perfusion and 1Na blockade were 
mainly due to inhibition of conduction in the SAN-SACP com­
partments (Fig. 8c-f), which directly correlate with functional 
mapping data (Figs. 1- 4). Figure 8c-e represents the space-time 
plot of action potential profiles recorded from cells along the mid­
line across the SAN-RA, showing continuous and stable action 
potential initiation and conduction at control condition, simu­
lated 25 pM adenosine, or 20% 1Na blockade in SAN (4% 1Na 
blockade in RA). However, consistent with results from our 
optical mapping study, in contrast to solely adenosine or 20% 1Na 
blockade, the combination of 25 pM adenosine and 20% 1Na
blockade led to 3:2 SAN exit block in SACP (Fig. 8f), suggesting 
that high levels of adenosine and HF-induced downregulation of 
multiple nNav in the RA could form a substrate for conduction 
blocks and rhythm failure. Under simulated HF conditions, 20% 
fibrosis was added to the SAN and SACP regions in the 2D 
human SAN computer models (Fig. 9a) and the resulting action 
potentials generated in SAN, SACP, and RA regions are displayed 
in Fig. 9b, respectively. Figure 9c shows that dose-dependent 1Na 
inhibition by itself primarily slows SAN conduction and causes 
exit block at ~35% 1Na blockade, with only ~10% SCL pro­
longation. However, the addition of even 10 pM adenosine lowers 
the threshold for SAN exit block, wherein complete exit block 
occurs at ~20% 1Na blockade. Conditions simulating HF further 
slow SAN conduction and lower the threshold for both exit block 
and SAN arrest in the presence of adenosine or 1Na blockade 
(Fig. 9d).
In the non-failing model, the lowest safety factor (SF) was 
found in the junction between SACP-RA at control conditions. 
Due to atrial influence, maximum diastolic potential decreased in 
SACP cells from — 56 mV at SAN-SACP junction to — 72 mV at 
SACP-RA junction, which significantly increased functional 1Na 
across the SACP (Supplementary Fig. 9). Adenosine 25 pM 
induced hyperpolarization of ~1.5m V across SAN-SACP-RA, 
which further increased functional 1Na in SACP junction by 21% 
and SF by 5.8%, thereby maintaining source-sink balance 
necessary for conduction. Blocking 1Na alone by 20% decreased 
SF by 14% in SACP junction. Under these conditions, adding 25 
pM adenosine effects to the model produced the same 
hyperpolarization as adenosine alone, but as 1Na was unavailable 
to compensate, a 3:2 SAN exit block was induced due to beat-to- 
beat decrease in SF to 1.003 during conduction and 0.904 during 
exit block. These results raised the possibility that the exit blocks 
could be caused by Nav channels in the atria rather than in the 
SAN-SACP. Hence, 1Na was blocked separately, only in the SAN- 
SACP or in the RA. Results showed that when Nav channels are 
blocked only in the SAN-SACP component in the model, there 
are depressive effects on SCL, SACT, and thresholds of SAN 
conduction failure, which are similar to those of the control 
model, where Nav channels were blocked globally (Supplemen­
tary Fig. 10a, b). However, when Nav channels are blocked (up 
40%) only in the RA, there is no SAN conduction failure 
clarifying that the exit blocks are mainly due to Nav channel 
blockade in the SAN-SACP (Supplementary Fig. 10c). The HF 
model had a similar pattern for SF across the SAN-SACP-RA 
with the lowest safety factor also found at the SACP-RA junction; 
however, a more pronounced effect on safety factor resulted from 
adenosine 25 pM =  26%, 1Na block 20% =  25% and adenosine 25 
pM +  1Na block 20% =  59% (a safety factor of 0.7981). Further­
more, the computational human SAN models were able to reveal 
the mechanism for only exit blocks but the absence of entrance 
blocks during atrial pacing in functional mapping experiments 
when Nav were blocked (Figs. 3, 4). Computational analyses in 
control and HF human SAN models revealed that safety factor in 
SACP junction is direction-dependent and it is higher for 
entrance (~1.03) vs. exit conduction (~0.86) at the exit block 
conditions, which underlie the absence of entrance blocks during 
slow atrial pacing and 1Na partial block (Supplementary Fig. 11). 
Importantly, as we have previously shown3, the absence of 
entrance blocks in SACPs during atrial pacing further inhibited 
excitability in the SACP and promotes occurrence of post-pacing 
exit block (Supplementary Fig. 11b) and SAN reentrant 
arrhythmias28, which can explain current experimental observa­
tions (Figs. 3, 4).
These results from computer simulations not only support our 
optical mapping findings, but also suggest that the importance of 
1Na in preserving SAN conduction is dose-dependently
Fig. 7 Nav subunits altered in chronic alcohol users and heart failure patients. a Nav mRNA levels altered in human sinoatrial node (SAN) and right atria 
(RA) by chronic alcohol use in non-failing human hearts. Control n = 5, chronic alcohol use n = 5. b Nav mRNA altered in SAN and RA in heart failure (HF) 
non-alcohol users. Non-failing n = 5, HF n = 8. Data distributions are presented as box plots with dots as individual observations. The center line within the 
box represents the median, the lower and upper bounds of box represent the interquartile range, and the whiskers indicate the maximum and minimum 
sample values. Statistical analysis was done using mixed models in package lme4 with patient, heart weight, and indicator variables for alcohol, smoking, 
drug abuse, and HF. Patient was considered a random effect, others as fixed effects. Source data are provided as a Source Data file.
augmented by adenosine, resulting in SAN function failure due to 
exit blocks in SACPs and complete SAN automaticity arrest 
(Fig. 9c).
Discussion
Here we report findings from near-infrared optical mapping that 
not only elucidate a previously unknown role for Nav channels29 
in the human SAN but also suggest that this functional con­
tribution of Nav may be unique to the human SAN, compared
with the previously demonstrated roles of Nav in other small30 
and large16 animal models. A major finding is that unlike cNav, 
nNav may predominantly contribute to SAN intranodal con­
duction, rather than atrial conduction. On the other hand, cNav 
play important roles in both SAN pacemaking and conduction, 
especially during adenosine or pacing-induced stress to prevent 
intranodal conduction failure. Furthermore, these functional 
observations are supported by higher expression of nNav (Nav1.1 
and 1.6) and lower expression of cNav1.5 in human SAN cardi- 
omyocytes vs. surrounding atrial tissue. Our data also show that
Fig. 8 Human non-failing SAN computer simulations define Nav's protective role in SAN pacemaking and conduction. a Geometry of 2D computer 
model. b Action potentials (A P) and their derivatives (dV/dt) show different electrophysiological (EP) characteristics of SAN, SACP, and RA cells in the 
current model. Propagation of APs along the middle axis of the 2D SAN-atrium are displayed from the top to bottom with time at control conditions (c), 
Ado (d), and sodium current (/Na) 20% blockade (e). Blue and red numbers indicate the conduction time from SAN leading pacemaker through SAN and 
SACP, respectively. f Left: Ado plus /Na blockade reproduced prolonged SCL and SAN exit block. Right: representative APs and derivatives. Ado adenosine, 
RA right atria, SACP sinoatrial conduction pathway, SACT sinoatrial conduction time, SAN sinoatrial node.
several nNav transcripts were vulnerable to selective remodeling 
associated with HF, cardiac hypertrophy and modifying risk 
factors including history of smoking and chronic alcohol con­
sumption. Biophysics-based computer modeling revealed 
compartment-specific mechanistic insights that suggest a pro­
tective role for 1Na against rhythm failure within the human SAN 
pacemaker-conduction complex, especially in HF.
The human SAN is protected by multiple fail-safe mechan- 
isms3, which are critical to ensuring adequate cardiac perfor­
mance as well as preventing SND and cardiac arrhythmias 
during pathophysiological conditions13. Currently, high-resolu- 
tion, near-infrared optical mapping is the only mapping techni­
que that is able to accurately identify intranodal conduction and 
hence capable of determining compartment-specific backup 
mechanisms2,3. Utilizing these high-resolution ex-vivo examina­
tions was critical in our goal to uncover the unique roles of nNav 
and cNav within the human SAN. In the current study, blockade 
of both cNav and nNav was observed to directly inhibit SAN 
automaticity (SCL) at physiological conditions, manifesting an 
essential role for Nav in maintaining human SAN pacemaking. 
However, SACT proportionally increased more than SCL (SACT/ 
SCL ratio) during Nav blockade, which suggests that SAN
impairments due to Nav dysfunction may predominantly be due 
to depressed SAN conduction rather than automaticity. Im por­
tantly, Nav blockade increased beat-to-beat variability in SAN 
intranodal conduction and SAN reentrant arrhythmias (Fig. 2). 
These results establish a significant role for Nav channels in 
maintaining stable intranodal conduction and robust protection 
of human SAN rhythm, in both HF and non-failing hearts. In the 
light of our findings, we suggest that impaired intranodal con­
duction could underlie clinically observed symptoms of familial 
sick sinus syndrome including sinus bradycardia/arrest in some 
patients carrying SCN5A mutations18"31.
Interestingly, although previous studies in animal models have 
identified a remarkable range of varying, species-specific roles for 
Nav isoforms in the SAN14- 16,30, our findings demonstrate that 
Nav channels may contribute very differently to human SAN 
pacemaking and conduction15,16,32. Studies have found that 
micromolar TTX can depress heart rate in adult mouse33 and 
rabbit SAN preparations34, providing evidence that cNav can 
contribute to SAN automaticity in some adult mammalian hearts. 
However, in contrast to the mouse SAN study30, where nano­
molar TTX impaired SAN automaticity but did not inhibit con­
duction, we found that nanomolar TTX impaired intranodal
Fig. 9 Heart failure increases SAN impairment caused by Nav blockade in computer simulations. a Geometry of the 2D computer model with 
unexcitable fibrosis elements shown in light blue. b Action potentials (A P) and their derivatives (dV/dt) show different electrophysiologic (EP) 
characteristics of SAN, SACP, and RA cells in the current model. Table results displaying combinations of adenosine dose and the percentage of sodium 
current (/N a) block in terms of cycle length, SACT, and threshold of SAN pacemaking and conduction impairment in control model (c) and HF model (d). 
Ado adenosine, HF heart failure, SACP sinoatrial conduction pathway, SACT sinoatrial conduction time, SAN, sinoatrial node, SCL sinus cycle length.
conduction (~250%) with negligible effects on SAN automaticity 
(~6%) and atrial conduction (~6%) at physiological conditions. 
Our data suggest that unlike other species, TTX-sensitive neu­
ronal 1N a, particularly nNav1.6 in addition to cardiac 1N a, may 
particularly be important in maintaining intranodal conduction 
within the human SAN.
Increased levels of adenosine have been shown to cause SND 
during metabolic stress and HF35,36. In the hum an SAN, 
adenosine-induced inhibition of SAN pacemaking and con­
duction are mainly due to activation of A1R and outward 
potassium current (1K>A do/A C h )3, which can significantly 
hyperpolarize SAN pacemaker cells37. Similarly, fast pacing or 
atrial arrhythmias could also increase the activation of outward 
K+  currents and reduce 1Ca,L, which inhibit the excitability of 
the SACPs more than intranodal pacemaker com partments and 
lead to post-pacing SAN exit block in diseased hearts2,38,39. 
Therefore, we used both adenosine and fast atrial pacing to
simulate a pathological scenario to investigate the role of Nav 
channels in this context. Our findings show that Nav blockade 
significantly exacerbated the depressive effects o f both adeno­
sine and overdrive suppression resulting in intranodal con­
duction failure and SAN arrhythmia. These findings are in 
keeping with previous results from isolated SAN cells, sug­
gesting that Nav could be preferentially activated when the cell 
is hyperpolarized16,17, which may be im portant to counteract 
impaired SAN-SACP excitability during pathological chal­
lenges. Our data suggest that TTX-sensitive nNav could play a 
distinct protective role in hum an SAN conduction, especially 
during pathological conditions including adenosine-mediated 
hyperpolarization, when the balance between the source (elec­
trical current/charge generated by the SAN and delivered 
through SACP) and sink (the current/charge required to acti­
vate the neighboring atrial myocardium) might be com pro­
mised (Figs. 3, 4).
Although direct experimental data confirming SACP-specific 
effects of 1Na are lacking for the human SAN, our human 
compartment-specific SAN-SACP-RA computer model indeed 
demonstrates decreased maximal diastolic potential and increased 
1Na activation across the SACP toward the RA. This unidirec­
tional increase in 1Na activation within the SACP could help 
maintain the source-sink balance. Computer simulations further 
demonstrate that adenosine-induced hyperpolarization and 1Na 
blockade can produce a synergistic negative effect, causing 
complete SAN exit block due to conduction failure in the SACP 
(Fig. 9 and Supplementary Figs. 10 and 11). Specific combinations 
of adenosine and 1Na blockade reproduced the beat-to-beat con­
duction variability and intermittent SAN exit block observed in 
our optical mapping experiments.
Recent studies have shown that in addition to cNav, multiple 
nNav are expressed in the human heart40; however, their presence 
in the human SAN has never been investigated. Nav channels are 
composed of one pore-forming a-subunit associated with two 
different ß-subunits41 and can be categorized as TTX-resistant 
(IC50 > 1 pM) cardiac isoforms and TTX-sensitive (IC50 < 60 nM) 
neuronal channels42. In this study, mRNA transcripts of both 
nNav and cNav isoforms were detected, with varying distribu­
tions between the SAN and RA. In the SAN, among the TTX- 
resistant Navs (1.5, 1.8, and 1.9), only cNav1.5 was found at 
significant levels, indicating that the observed additional func­
tional effects during high-dose TTX could be mediated mainly by 
cNav1.5. Importantly, the higher protein expression of nNav1.6 
compared with cNav1.5 channels in SAN vs. RA may also explain 
the higher sensitivity of SAN to nanomolar TTX compared to 
surrounding atrial tissue. In fact, the specific nNav1.6 blocker 
depressed SAN function similar to the effects of 100 nM sug­
gesting that the effect of TTX 100 nM in the human SAN studied 
may be partially mediated by nNav1.6; furthermore, higher ratio 
of nNav1.6 between SAN and RA was found in the heart that 
developed exit block with nNav1.6 blocker, compared with two 
other hearts that exhibited less sensitivity to nNav1.6 blocker. 
These results from the limited number of human hearts studied 
suggest that nNav1.6 plays an important role in preserving 
human SAN conduction potentially by preventing exit blocks. 
However, expression of other nNav isoforms and accessory/ 
interacting proteins should also be investigated in future studies, 
to determine their mechanistic roles in SAN function.
Previous studies have shown that many cardiac diseases can 
cause remodeling of major ion channels10- 13 including HCN1 
and HCN4, A1R, and L-type calcium channels. Indeed, we found 
significantly lower mRNA levels of almost all nNav isoforms in 
HF hearts, especially nNav1.6 in the SAN (Fig. 7). Interestingly, 
our data from the limited number of hearts studied show that 
nNav transcript levels in the human SAN and RA are also 
associated with other modifying risk factors including chronic 
alcohol consumption. As chronic alcohol consumption has been 
strongly associated with arrhythmias including ventricular 
tachycardia and AF43, our data indicate that Nav channels must 
be studied in larger samples of hearts from chronic alcohol abuse 
patients to potentially reveal Nav-mediated arrhythmic mechan­
isms associated with chronic alcohol consumption. Interestingly, 
as shown in Fig. 4, our optical mapping data revealed that sub­
sequent to nNav and partial cNav blockade, hearts with history of 
chronic alcohol consumption or HF were highly susceptible to 
SAN intranodal conduction disturbances leading to atrial beat-to- 
beat variability, SAN reentrant arrhythmias, and sinus arrest.
From a clinical standpoint, as adenosine’s effects on the SAN 
are similar to those of vagal stimulation37, our findings emphasize 
avoiding/limiting the use of drugs that may block TTX-sensitive 
1Na, especially when vagal tone is high, or in HF36 and AF44 
patients with high plasma levels of adenosine. Our results also
identify the human SAN as a direct target for several clinical 
medications designed to block Nav channels, including Class I 
antiarrhythmic drugs that block Nav1.5, some anesthetics, and 
pain medications that block nNav. In fact, flecainide, a clinically 
prescribed Class I antiarrhythmic drug, has been reported to 
increase cSNRTi in SND patients20 and to significantly reduce 
heart rate during exercise in patients with normal cardiac struc­
ture and SAN function45. The availability of Nav channels in the 
human SAN and RA could be an important backup mechanism 
to robustly protect SAN conduction and pacemaking, and prevent 
exit blocks and source-sink mismatch, in the context of multiple 
disease-induced conduction impairments3,46.
Similar to other human studies, our data are also limited by the 
small number of ex-vivo human atrial preparations with varied 
pre-existing disease etiologies, which may not be representative of 
all human atria. As the data are from HF patients that have been 
treated long-term with several medications, disease-independent 
drug-induced effects could also have affected Nav transcript 
levels. Few HF hearts were available for optical mapping studies 
due to bicaval surgical dissection, which can impair SAN cor­
onary artery perfusion. We were unable to confirm protein 
expression of all Nav isoforms transcripts detected in the mRNA 
studies due to the lack of specific antibodies suitable for human 
tissues. Furthermore, due low sample numbers we could not 
directly certify the correlation between Nav-related SAN pace- 
making/conduction dysfunction and HF or alcohol consumption 
in optical mapping experiments. Additional studies should record 
1Na from isolated human SAN cardiomyocytes, in order to dif­
ferentiate the specific contributions of cNav and nNav to cellular 
activation, relative to other ion currents including and 1Ca.
These findings provide insights to clarify the role of nNav and 
cNav isoforms in maintaining the robustness of the human SAN 
and establish Nav channels as important players essential to 
protect intranodal conduction and prevent rhythm failure.
Methods
Patient groups included in the study. All hum an heart tissue research were 
approved by The Ohio State University Institutional Review Board and in com ­
pliance with all relevant ethical regulations. Inform ed consent for tissue collection 
was obtained from  transplant patients and families of donors. H um an hearts used 
in this study were de-identified and labeled with 6  digit random  codes for reference. 
Hearts with intact SAN pacemaker complexes from  transplant patients (with left 
ventricular hypertrophy, ischemic and non-ischem ic HF, AF, and comorbidities 
including chronic H TN  and diabetes) and hum an donor hearts (w ithout history of 
H F and AF but with comorbidities including HTN, diabetes, and modifying risk 
factors including history o f smoking, chronic alcohol consum ption/abuse (n =  34, 
19-68 y/o, details in Supplementary Tables 1 and 2) were obtained from The Ohio 
State University C ardiac Transplant Team or LifeLine o f Ohio Organ Procurem ent 
Organization. Chronic Alcohol Consum ption is defined as either abuse ( >  7 
drinks/week for women and > 14 drinks/week for men), as reported in documented 
medical records, or chronic consum ption of moderate drinking ( >  2  drinks/week 
for at least 10 years). Alcohol consum ption was first collected from medical records 
when available and then from retrospective interviews with family members by 
LifeLine of Ohio Organ Procurem ent Organization for rejected donor hearts and 
drug abuse as listed in the patient’s electronic health record. Expanded Materials 
and M ethods are provided in the Supplementary Material.
Near-infrared optical mapping and data analysis. Conventional clinical 
electrode-based m apping systems are unable to record intram ural conduction and 
activation patterns from w ithin the 3D hum an SAN in patients, yet we were able to 
overcome these limitations by utilizing our recently validated high-resolution near- 
infrared optical m apping3. H um an SAN preparations (n =  14) were coronary- 
perfused and stained with near-infrared dye di-4-ANBDQBS3. Regions o f poor 
coronary perfusion/ischemia were excluded. To distinguish the function of dif­
ferent classes of Nav in the hum an SAN, two different doses o f TTX (Abcam), 100 
nM  and 1-3 [±M, were sequentially perfused through the coronary arteries. Lower 
dose, 100 nM  TTX, selectively blocks majority o f TTX-sensitive nNav subtypes 
(such as Nav1.1-1.3 and Nav1.6-1.7 with IC5 0  ~10nM ), but not TTX-resistant 
cNav1.5 with IC5 0  > 1 [iM.42. As the majority o f nNav were already blocked, any 
further effects at the higher dose, TTX 1-3 ^M, was attributed to blockade o f TTX- 
resistant cNav1.5. Optical m apping was conducted with MiCAM Ultima-L CMOS 
cameras with resolution up to 330 pm 2  (100 x 100 pixels)3. Optical m apping
identified the leading pacemaker or earliest SAN depolarization, as well as earliest 
atrial activation sites, where activation exited to the atria through SACPs. SACT 
reports the time of activation propagation from  the SAN leading pacemaker to the 
earliest atrial activation site. SAN activation patterns, SCL, SACTsr, or after atrial 
pacing (SACTppb), and corrected direct/indirect sinus node recovery time 
(cSNRTd/i) were measured during constant perfusion of Tyrode’s solution at 
control (n =  10), and sequential perfusion of 100 nM  (n =  8 ) and 1-3 pM (n =  7) 
TTX. Overdrive atrial pacing (CL =  500 ms, 400 ms, and 300 ms) and adenosine 
bolus (1 mL, 10-100 pM) were used to challenge the robustness of SAN pace- 
making and conduction. RA CV was measured by RA pacing at 500 ms. In 
addition, a specific Nav1.6 blocker 4,9-Anhydrotetrodotoxin (30 nM ) 2 7  was used in 
a subset of four hearts studied with the same protocols as for TTX above. Nav1.6 
blocker was tested in five experiments with H eart 957855 tested before and after 
washout and addition of 1 nM  isoproterenol (Supplementary Fig. 1 and Supple­
m entary Table 1). W hen several drug protocols were studied, the first drug studied 
was washed out from SAN preparations and isoproterenol 1-10 nM  may have been 
used to recover sinus rhythm  to its baseline levels before the effect of Nav blockade 
was studied (Supplementary Tables 6  and 7).
Molecular mapping and data analysis. To molecularly map mRNA, protein 
expression, and distribution of nNav and cNav, pure SAN and surrounding atrial 
tissues were collected from 2 0  unm apped hum an hearts (non-failing =  1 0 ; failing 
=  10) guided by im m unostaining and M asson’s trichrom e stain3 ,4  (Supplementary 
Fig. 12). Total RNA and proteins were extracted separately from the SAN and 
surrounding atrial tissue4,10. qPCR was conducted in duplicates with QuantStudio 
3 (Applied Biosystems), SYBR green (Qiagen), and QuantiTect prim er assays 
(Qiagen; Supplementary Table 8 ). Comparative threshold cycle (Ct) was used to 
compare the relative abundance of mRNAs in the samples. Primary antibodies 
against Nav1.5 (custom-made in D r M ohler’s lab), Nav1.6 (Alomone), Connexin- 
43(Cx43), Glyceraldehyde 3-phosphate dehydrogenase, and a-actinin (Sigma- 
Aldrich) were used to quantify corresponding proteins by western blotting and 
im m unostaining3 ,4  (Supplementary Table 9). Uncropped versions of blots have 
been provided in Source Data file.
Human compartment-specific SAN-SACP-RA computational model. A
biophysics-based 2D com putational model was designed based on our study of 
hum an SAN structure2  to simulate the interactions between SAN, SACP, and RA. 
The hum an SAN and SACP were modeled with the Fabbri et al. model47, based on 
isolated hum an SAN pacemaker cell recordings48, and adapted with optical 
mapping data from central SAN and SACP regions, respectively (Supplementary 
Table 10). The RA cells were modeled by using the original hum an atrial Cour- 
temanche et al. cell model49. The ratio of INa blockage in SAN vs. RA was set to 5:1. 
To incorporate the effects of adenosine into the cellular models, we utilized the 
acetylcholine (ACh)-activated K+ current, IK,ACh/Ado, previously used for the 
atria4 9  and SAN models47, equating ACh concentrations with those of adenosine 
based on our optical experiments. In HF SAN model (Fig. 9a), 20% reduction in If 
current and heterogeneously seeded fibrosis with a size of 2 x  2 within SACP 
regions with a ratio of 1:4 to the norm al SAN/SACP cells were implemented, as 
well as 20% and 5% reduction in the INa current in SAN-SACP and atrial cells, 
respectively.
Conduction am ong SAN/atrial cells was modeled using a m ono-dom ain 
equation and solved using a paralleled finite difference approach50. W e used a 
spatial step of 0.03 m m  and tem poral step of 0.0025 ms in our solver. A forward 
Euler m ethod5 0  was used to solve the ordinary differential equations of cellular 
models. The conduction in the 2D tissue model attributable to intercellular electric 
coupling via gap junctions was modeled through the diffusion coefficient. In this 
model, we considered the regional differences in gap junctional coupling between 
the SAN, SACP, and RA tissues by setting the diffusion coefficient ratio to 2:14:100 
in these three regions. The SF5 1  was calculated to measure the success of 
propagation at each cell and is defined as the ratio of the total charge produced to 
the total charge consumed at that cell. If the ratio is less than 1, inefficient charge is 
produced for downstream activation and propagation will fail.
Statistical analysis. Data are presented as m ean ± SD. All the statistical analyses 
were done in R 3.4.4 using packages lme4 and emmeans. The mixed models 
included Heart and Category (control, TTX 100 nM  and TTX 1-3 pM) as pre­
dictors. Heart was treated as random  effect and Category as fixed effect. Pairwise 
tests between condition levels were adjusted using Tukey’s method. Quality of fit 
was m onitored by visual inspection of residuals. Analysis of variance model was 
used to compare Categories. Analysis of the ratios for TTX 100 nM  and TTX 1-3 
pM categories compared with control was done using two-tailed t-test. Normality 
assumption was verified using Shapiro-W ilk test. Non-param etric data were 
analyzed with two-sided W ilcoxon’s test. Analysis of exit block events was done 
using two-sided proportion test with Yates continuity correction. Association 
analysis of Nav isoform transcription level with diseases was done using mixed 
models in package lme4 with heart/patient, heart weight, and indicator variables 
for age, gender, smoking, chronic alcohol consumption, HF, AF, or HTN. Heart/ 
patient was considered a random  effect, others as fixed effects. P-values < 0.05 were 
considered significant.
Reporting summary. Further inform ation on research design is available in 
the Nature Research Reporting Summary linked to this article.
Data availability
Raw source data underlying all reported averages in graphs and charts, and uncropped 
versions of blots presented in the figures are available as a Source Data file. The source 
data underlying Figs. 1c, 2d, 3c, 5, 6  immunostaining, 6  western blotting, Table 1, and 
Supplementary Figs. 5, 7 are found in the source data file. All data are presented within 
the manuscript, the online data supplemental file, or are available upon reasonable 
request to the corresponding author.
Code availability
The ionic model utilized4 7  is freely available from the repository CellML (https://www. 
cellml.org/). Link to computer model source code, the test and readme files are provided 
here: https://github.com/Charcol97/Fabbri_HumanSAN_OSU
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